Profusa Expands European Footprint With New Collaborations, Prepares for Investor Spotlight
Digital health company secures partnerships in Belgium and Austria while CEO readies for major investor conference.
Profusa (NASDAQ: PFSA) is quickly building momentum across Europe, adding leading vascular specialists to its clinical network while also preparing to highlight its technology platform to global investors. The Berkeley, California–based company, known for its pioneering Lumee™ Oxygen monitoring system, announced back-to-back partnerships in Belgium and Austria and confirmed participation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
Expanding Reach in Belgium
Profusa’s latest agreement in Belgium marks a significant milestone. The company has partnered with AZ Sint Blasius Hospital, where Dr. Koen R. Deloose, head of vascular surgery, will spearhead the adoption of the Lumee system. Dr. Deloose, a widely recognized expert in critical limb ischemia (CLTI), treats more than 300 CLTI patients each year.
Dr. Deloose stated:
I personally used the Lumee™ Oxygen measurement to monitor endovascular revascularization procedures in below the knee cases. Profusa’s technology provides a critical real-time tissue oxygen perfusion metric that is essential for our successful treatment of these patients. My case data highlighted the relationships between oxygen dynamics measured at point locations, anatomical target of delivered interventions, and treatment outcome. I’m convinced this technology will offer us more guidance in the treatment and follow-up of a constantly growing CLTI-population.
Profusa Chairman and CEO Ben Hwang, Ph.D., welcomed the addition, noting the alignment with the company’s mission. “We continue to add to our impressive roster of customers and warmly welcome Dr. Deloose to our network,” he said.
Clinical Collaboration in Austria
Just a week earlier, Profusa unveiled another partnership, this time in Austria with Prof. Dr. Marianne Brodmann at the Medical University of Graz. Dr. Brodmann, who has overseen clinical studies that supported Lumee’s CE marking, will adopt the oxygen monitoring platform across her practice of approximately 1,500 vascular procedures each year.
Dr. Brodmann commented:
Real-time oxygen perfusion data for patients suffering from critical limb ischemia is critical for the proper monitoring of patients during surgery and as they recover. As an experienced user of Profusa’s technology through leading portions of Profusa’s clinical studies, I am convinced that the Lumee Oxygen platform meets an important clinical need.
Dr. Brodmann’s long-standing leadership in European vascular medicine lends further credibility to Profusa’s system, and her integration of the platform into clinical programs underscores its growing role in patient care.
Also Read: Why This Tiny Wearable Tech Stock Looks Poised for a Massive Breakout
Taking the Stage in New York
Profusa’s growth story is not limited to Europe. The company confirmed that CEO Ben Hwang will deliver a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, held September 8–10, 2025, at the Lotte New York Palace Hotel. The presentation will be available on demand for registered investors starting September 5.
The high-profile event features leading industry voices, one-on-one investor meetings, and networking opportunities, giving Profusa a chance to showcase its clinical traction to the financial community.
Building Toward Broader Adoption
By aligning with renowned vascular specialists in Europe and stepping onto one of the industry’s biggest investor stages, Profusa is signaling its ambitions to scale its biosensor platform globally. The dual focus, expansion in clinical practice and visibility with investors suggest that the company is positioning itself for both near-term adoption and long-term growth.
With its technology addressing critical needs in vascular care, and with momentum from strategic partnerships, Profusa is moving quickly from clinical promise toward broader commercialization.
Read Now: Why Big Investors Who Can’t Buy Crypto Are Gobbling Up These Stocks Instead
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $125,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
